PreOperative Brain Irradiation in Glioblastoma (POBIG)
Research type
Research Study
Full title
PreOperative Brain Irradiation in Glioblastoma (POBIG)
IRAS ID
288337
Contact name
Gerben Borst
Contact email
Duration of Study in the UK
1 years, 6 months, 27 days
Research summary
Glioblastoma is the most common primary malignant brain tumour in adults. Its outcomes are poor due to local disease progression in most patients. Current treatment includes surgery followed by chemotherapy and radiotherapy 4-6 weeks after surgery. In this time interval, some tumour cells do not receive any treatment. Furthermore, studies show that around half of all glioblastoma patients experience rapid early progression (REP) i.e. growth of the tumour in the time interval between surgery and postoperative chemotherapy/radiotherapy. REP is associated with a shorter survival and there are currently no effective treatments or preventative measures to address it. Radiotherapy delivered earlier before the operation could prevent REP and improve patient outcome. In this phase I study - PreOperative Brain Irradiation in Glioblastoma (POBIG), we will test the safety and feasibility of giving a single dose (fraction) of radiotherapy before surgery in patients with a new radiological diagnosis of glioblastoma. This study will be a dose escalation study to determine the maximum tolerated dose of preoperative radiotherapy and maximum volume of tumour that can be safely irradiated preoperatively. This study will take place over 18 months. We hypothesise that preoperative radiotherapy will reduce the rate of REP and improve patient outcome.
REC name
North West - Greater Manchester South Research Ethics Committee
REC reference
21/NW/0121
Date of REC Opinion
8 Jul 2021
REC opinion
Further Information Favourable Opinion